Further phenotypic interrogation of these tumour ILC1s revealed an overall transition from expression of activating receptors [e.g., killer cell lectin-like receptor D1 (Klrd1), natural cytotoxicity triggering receptor 1 (NKp46), killer cell lectin-like receptor C2 (Klrc2), killer cell lectin-like receptor subfamily B member 1C (Klrb1c)] in early disease stage towards inhibitory receptors [e.g., killer cell lectin-like receptor family E member 1 (Klre1), killer cell lectin-like receptor subfamily A (Klra)] in late stage cancer. Here, NCR1 is linked to neoplasm.